# Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

> **NCT00217399** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **DRUG:** anastrozole

## Key facts

- **NCT ID:** NCT00217399
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2009-07
- **Final completion:** 2013-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217399, "Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00217399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*